Inhaled Messenger RNA Treatment Fast-Tracked for Cystic Fibrosis
The FDA has granted Fast Track designation to MRT5005, an inhaled messenger RNA (mRNA) therapeutic being investigated for the treatment of cystic fibrosis.
Obstructive Lung Disease
Ultrasound May Identify Children at Risk for Cystic Fibrosis Liver Disease
A heterogeneous liver pattern could indicate a higher risk for advanced cystic fibrosis liver disease.
Investigational Antibiotic Receives Orphan Drug Status for CF Pulmonary Exacerbations
The FDA has granted Orphan Drug designation to ARV-1801 (sodium fusidate; Arrevus) for the treatment of pulmonary exacerbations in patients with cystic fibrosis.
Continuous Glucose Monitoring in Youth With Cystic Fibrosis May Detect Early Diabetes
Continuous glucose monitoring may provide a better understanding of the early stages of diabetes progression in youth with cystic fibrosis.
Nontuberculous Mycobacterial Infection in Cystic Fibrosis: Treatment Recommendations
A multidisciplinary team discussed exploring the management options for nontuberculous mycobacterial infection in patients with cystic fibrosis.
Differences in BAL Surveillance of Preschool Children With Cystic Fibrosis
Significant differences have been observed from bronchoalveolar lavage surveillance conducted among preschool children with cystic fibrosis, according to their country of residence.
Diversity of Mycobacterium abscessus Subclones in Pediatric Cystic Fibrosis
Sputum isolates of Mycobacterium abscessus may not reflect a patient’s full bacterial diversity.
Controlling Antibiotic Adverse Drug Reactions in Cystic Fibrosis
The majority of patients with cystic fibrosis experience at least 1 antibiotic adverse drug reaction.
Long-Term Azithromycin Reduced Need for IV Antibiotics in Cystic Fibrosis
Treatment with azithromycin during a 5-year period was associated with reductions in the use of intravenous antibiotics and pulmonary exacerbations in children with cystic fibrosis.
Elexacaftor-Tezacaftor-Ivacaftor Efficacious for Cystic Fibrosis
The percentage of FEV1 higher was at 4 weeks and through 24 weeks with treatment vs placebo.
Next post in Obstructive Lung Disease
